Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Daniel Rivera, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Michael Andreeff, MD PhD, Kapil N. Bhalla, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-142043

Published: 2020

Journal Articles

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Daniel Rivera, MD, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Lingsha Zhou, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Lucia Masarova, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142650

Published: 2020

Journal Articles

Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience

Javier Checa, Óscar Javier Blanco Núñez, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Daniel Rivera, MD, Alejandro Avendaño Pita, MD, Antonio velasco Guardado, PhD, Miguel Alcoceba, PhD, Luis Miguel Chinchilla Tábora, MD, Dolores Caballero, MD, Lucia Lopez Corral, PhD MD

Blood (2018) 132 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2018-99-114587

Published: 2018

Journal Articles

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Blood (2018) 132 (Supplement 1): 200.

https://doi.org/10.1182/blood-2018-200

Published: 2018

Journal Articles

Senescent Mesenchymal Stem Cells Present at the Early Post Allogeneic Hematopoietic Stem Cell Transplantation Period Are Associated with an Increased Incidence of Acute Graft-Versus Host Disease and Increased Plasma Levels of Fas Ligand

Daniel Rivera, MD, Lika Osugui, PhD, Sandra Muntion, PhD, Miguel Alcoceba, PhD, Concepcion Rodriguez, Rebeca Ortega, Natalia Espinosa, MD, Ana Gomez de la Torre, Ana Rico, Miriam López-Parra, MD, Alba Redondo, MD, Eva Villarón, Félix López Cadenas, MD, Silvia Preciado, Maria Díez-Campelo, Lucía López Corral, MD, Marcos González, MD PhD, Dolores Caballero, MD, Fermin Sanchez-Guijo, MD PhD

Blood (2018) 132 (Supplement 1): 2116.

https://doi.org/10.1182/blood-2018-99-115363

Published: 2018

Journal Articles

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Daniel Rivera, MD, Jose Maria Bastida, MDPhD, Lucia Lopez Corral, PhD MD, Fermin Sanchez-Guijo, MD PhD, Lourdes Vázquez, MD, Monica Cabrero, MD, Estefania Pérez-López, MD, Miriam López-Parra, MD, Ana A. Martín, MD, Javier Carrillo, MD, Alejandro Avendaño, MD, Alvaro Veiga, MD, Monica Baile, MD, Nerea Arratibel, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Jose Ramon González-Porras, MDPhD

Blood (2017) 130 (Supplement 1): 3222.

https://doi.org/10.1182/blood.V130.Suppl_1.3222.3222

Published: 2017

Journal Articles

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Alvaro Veiga, MD, Alba Redondo, MD, Miriam López-Parra, MD, Olga López-Villar, MD, Eva Villarón, Maria Díez-Campelo, MD PhD, Daniel Rivera, MD, Natalia Espinosa, MD, Nerea Arratibel, MD, Mónica Baile, MD, Estefania Pérez-López, MD, Mónica Cabrero, MD, Ana A. Martín, MD, Lourdes Vázquez, MD, Lucía López Corral, MD, Dolores Caballero, MD PhD, Consuelo Del Cañizo, MDPhD, Fermin Sanchez-Guijo, MD PhD

Blood (2017) 130 (Supplement 1): 1981.

https://doi.org/10.1182/blood.V130.Suppl_1.1981.1981

Published: 2017

NARROW

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Senescent Mesenchymal Stem Cells Present at the Early Post Allogeneic Hematopoietic Stem Cell Transplantation Period Are Associated with an Increased Incidence of Acute Graft-Versus Host Disease and Increased Plasma Levels of Fas Ligand

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Outcomes of Patients with Myelofibrosis and Favorable Karyotype

Intestinal Transplant-Associated Thrombotic Microangiopathy: Histopathological Review. a Single Center Experience

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Senescent Mesenchymal Stem Cells Present at the Early Post Allogeneic Hematopoietic Stem Cell Transplantation Period Are Associated with an Increased Incidence of Acute Graft-Versus Host Disease and Increased Plasma Levels of Fas Ligand

Usefulness of Thrombopoietin Receptor Agonists for Thrombocytopenia after Allogeneic Stem Cell Transplantation. An Eight-Year Single Center Experience

Mesenchymal Stromal Cells for Refractory Acute Graft-Versus-Host Disease By Compassionate Use Provide Comparable Results to Those of Phase II Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only